- Home
- ROIV vs MLM Comparison
ROIV vs MLM Comparison
Compare ROIV & MLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | MLM |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 34.4B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ROIV | MLM |
|---|---|---|
| Price | $35.43 | $478.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 24 |
| Target Price | $48.08 | ★ $635.17 |
| AVG Volume (30 Days) | ★ 6.0M | 759.5K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 29.27 |
| Revenue | $8,260,000.00 | ★ $6,150,000,000.00 |
| Revenue This Year | $530.75 | $27.17 |
| Revenue Next Year | $685.92 | $23.04 |
| P/E Ratio | ★ N/A | $16.45 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.99 | $470.19 |
| 52 Week High | $42.50 | $710.97 |
Technical Indicators
Market Signals| Indicator | ROIV | MLM |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 38.57 |
| Support Level | $33.15 | $470.19 |
| Resistance Level | $35.70 | $636.33 |
| Average True Range (ATR) | 1.14 | 12.10 |
| MACD | -0.34 | 1.10 |
| Stochastic Oscillator | 35.90 | 21.07 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MLM Martin Marietta Materials Inc.
Martin Marietta is a leading US producer of construction aggregates, having produced roughly 200 million tons in 2025. Its aggregate reserves represent approximately 85 years of supply at 2025 production levels. Over the past several years, the company has increased its exposure to aggregates while reducing its presence in cement and downstream businesses such as concrete and asphalt. More recently, Martin Marietta expanded into an aggregate-adjacent business through its acquisition of Lhoist North America, the largest US producer of lime. The company operates across 28 states, with smaller operations in Canada and the Bahamas.